434 related articles for article (PubMed ID: 9193198)
1. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.
Kramer MS; Last B; Getson A; Reines SA
Arch Gen Psychiatry; 1997 Jun; 54(6):567-72. PubMed ID: 9193198
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.
Schmidt ME; Kent JM; Daly E; Janssens L; Van Osselaer N; Hüsken G; Anghelescu IG; Van Nueten L
Eur Neuropsychopharmacol; 2012 Oct; 22(10):721-33. PubMed ID: 22464973
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.
Corrigan MH; Gallen CC; Bonura ML; Merchant KM;
Biol Psychiatry; 2004 Mar; 55(5):445-51. PubMed ID: 15023570
[TBL] [Abstract][Full Text] [Related]
6. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
Lerner V; Bergman J; Statsenko N; Miodownik C
J Clin Psychiatry; 2004 Nov; 65(11):1550-4. PubMed ID: 15554771
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
8. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
[TBL] [Abstract][Full Text] [Related]
9. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
[TBL] [Abstract][Full Text] [Related]
10. Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia.
Truffinet P; Tamminga CA; Fabre LF; Meltzer HY; Rivière ME; Papillon-Downey C
Am J Psychiatry; 1999 Mar; 156(3):419-25. PubMed ID: 10080558
[TBL] [Abstract][Full Text] [Related]
11. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
12. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
13. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
14. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D4 receptors: a new opportunity for research on schizophrenia.
Liégeois J; Eyrolles L; Bruhwyler J; Delarge J
Curr Med Chem; 1998 Apr; 5(2):77-100. PubMed ID: 9481035
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
18. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Meltzer HY; Arvanitis L; Bauer D; Rein W;
Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
[TBL] [Abstract][Full Text] [Related]
20. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
